Myocardial Ischemia Global Market Report 2024

Myocardial ischemia, also known as cardiac ischemia, occurs when there is reduced blood flow to the heart muscle, resulting in insufficient oxygen and nutrient delivery. This condition can lead to potential damage to the heart muscle. The primary cause of myocardial ischemia is the narrowing of coronary arteries due to the buildup of plaque, which limits blood flow.

There are two main types of myocardial ischemia, symptomatic and asymptomatic. Symptomatic myocardial ischemia refers to cases where individuals experience symptoms such as chest pain or discomfort (angina) during episodes of reduced blood flow to the heart muscle. Various treatments and diagnostic approaches are utilized by different end-users including hospitals, clinics, diagnostic centers, and ambulatory surgery centers.

The myocardial ischemia market research report is one of a series of new reports that provides myocardial ischemia market statistics, including myocardial ischemia industry global market size, regional shares, competitors with a myocardial ischemia market share, detailed myocardial ischemia market segments, market trends, and opportunities, and any further data you may need to thrive in the myocardial ischemia industry. This myocardial ischemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The myocardial ischemia market size has grown strongly in recent years. It will grow from $0.74 billion in 2023 to $0.79 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to the utilization of telemedicine and remote monitoring, the development of novel reperfusion therapies for myocardial infarction (MI), increased cases of obesity, higher prevalence of high blood pressure, and an increase in the incidence of heart attacks.

The myocardial ischemia market size is expected to see strong growth in the next few years. It will grow to $1.04 billion in 2028 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to the prevalence of various heart-related diseases, increasing awareness among the population about cardiovascular diseases, evolving lifestyles, rising cases of diabetes, and higher healthcare expenditures. Major trends anticipated during this period include the adoption of advanced treatments for myocardial ischemia, improvements in healthcare infrastructure, advancements in treatment options, integration of digital health solutions, and the introduction of cardiac rehabilitation programs.

The increasing prevalence of diabetes is expected to drive growth in the myocardial ischemia market. Diabetes comprises a group of metabolic disorders characterized by the body's ineffective use of insulin, crucial for regulating blood sugar levels. Factors contributing to the rising incidence of diabetes include obesity, sedentary lifestyles, and genetic predisposition. This higher prevalence of diabetes correlates with increased occurrences of myocardial ischemia, prompting greater demand for diagnostic, therapeutic, and management solutions for this condition. For instance, the International Diabetes Federation reported in 2021 that approximately 537 million adults aged 20-79 worldwide had diabetes, a number projected to increase to 643 million by 2030 and 783 million by 2045. Thus, the rising incidence of diabetes serves as a catalyst for the myocardial ischemia market's expansion.

Key players in the myocardial ischemia market are focusing on developing innovative medications such as Lodoco (colchicine) to address inflammation and reduce cardiovascular risk in patients with coronary artery disease. Lodoco is specifically indicated to lower the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple cardiovascular risk factors. For example, Agepha Pharma, a US-based pharmaceutical firm, launched Lodoco (colchicine) in June 2023, following approval by the US Food and Drug Administration (FDA). This approval marked a significant milestone as the first FDA-approved treatment targeting cardiovascular inflammation. Clinical trials, including LoDoCo2, demonstrated a 31% relative risk reduction in cardiovascular events with colchicine 0.5 mg once daily compared to placebo. Lodoco is prescribed to mitigate the risk of serious cardiovascular events in eligible patients.

In December 2021, Pfizer, a prominent US-based pharmaceutical company, acquired Arena Pharmaceuticals for $6.7 billion, expanding its portfolio and capabilities in inflammation and immunology. This acquisition strengthens Pfizer's position in developing breakthrough treatments for immuno-inflammatory diseases, including myocardial ischemia. Arena Pharmaceuticals, a US biopharmaceutical firm, offers therapeutic solutions for myocardial ischemia.

Major companies operating in the myocardial ischemia market are Cardinal Health Inc., Pfizer Inc., Roche Holding AG, Bayer AG, Sanofi SA, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories Inc., Eli Lilly and Company, Novo Nordisk A/S, Medtronic Plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Siemens Healthineers AG, Merck KGaA, GE HealthCare Technologies Inc., Fujifilm Holdings Corporation, Baxter International Inc., Regeneron Pharmaceuticals Inc., Boston Scientific Corporation, Daiichi Sankyo Company Limited, Canon Medical Systems Corporation.

North America was the largest region in the myocardial ischemia market in 2023. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial ischemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the myocardial ischemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myocardial ischemia market consists of sales of statin, anticoagulants, and antiplatelet agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.